Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor

por Dowell, James A., Dickerson, Daniel, Henkel, Tim
Publicado 2021

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment

por Dowell, James A., Marbury, Thomas C., Smith, William B., Henkel, Tim
Publicado 2022

2513. CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy in the Treatment of Complicated Urinary Tract Infections (cUTI)

por Dorr, Mary Beth, Gasink, Leanne, Henkel, Tim, Moeck, Greg, Chen, Hongzi, McConnell, Scott A, McGovern, Paul
Publicado 2023

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment

por Geibel, Brooke, Dowell, James A, Marbury, Thomas C, Smith, William, McGovern, Paul C, Richards, Cynthia, Henkel, Tim
Publicado 2020

731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)

por McGovern, Paul C, Wagenlehner, Florian, Gasink, Leanne, Moeck, Greg, McLeroth, Patrick L, Beth, Mary, Dane, Aaron, Henkel, Tim
Publicado 2022

2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study

por Moeck, Greg, Gasink, Leanne, Dorr, Mary Beth, Chen, Hongzi, Woosley, Leah, Mendes, Rodrigo E, Wagenlehner, Florian, Henkel, Tim, McGovern, Paul
Publicado 2023